Epidemiology and Prognosis of Encephalitis in Intensive Care

Overview

Introduction: Acute encephalitis (AE) is a severe neurological disorder associated with significant morbidity and mortality. Approximately 50% of patients with AE require ICU admission because of coma, seizures or acute respiratory failure. Determinants of neurological prognosis in these patients are not known. Objectives: Main objective: To identify determinants of outcome in adult patients admitted to the ICU; Secondary objectives: a) To study the impact of diagnostic studies (Brain MRI, CSF analysis, EEG) on neurologic outcome; b) to describe the epidemiology of patients admitted to the ICU with AE; c) to study the impact of early appropriate therapy on neurologic outcomes; d) to describe morbidity and mortality associated with AE at 90 days and 1 year following diagnosis. Methods: prospective observational multicenter study in French ICUs. All patients admitted to the ICU for probable or confirmed AE (2013 IDSA criteria)with a Glasgow coma scale score \< or =to 13 will be eligible for inclusion. Factors associated with a poor prognosis at 90 days will be identified by multivariable logistic regression analysis. Duration of study: 30 months (recruitment 18 months, follow-up 12 months). Patients: 300 patients Endpoints: * Primary endpoint: The primary endpoint is the modified Rankin scale score 90 days following onset of abnormal status (GCS \< or =13). This score will be determined by contacting the patient. A poor outcome will be defined as a mRS \>2 at 90 days. * Secondary endpoints: a) neurological findings within 7 days following onset of altered mental status; b) abnormal findings on diagnostic studies (MRI, EEG, CSF analysis) within7 days following onset of altered mental status; c) Time between onset of altered mental status and completion of diagnostic studies; d)Time between onset of altered mental status and start of appropriate specific therapy; e) neurologic outcomes at 1 year mRS score and extended Glasgow outcome scale (GOS); f) causes of death in non-survivors at 1 year; g) quality of life and posttraumatic stress at 1 year: IADL and SF36 scales;

Acute encephalitis (AE) is a serious condition associated with significant morbidity and mortality. Patients require ICU admission in 60 % of cases, mainly because of neurological symptoms (coma, seizures) or acute respiratory failure. The etiological profile of AE has changed considerably in recent years, with the emergence of new pathogens and the description of new immune-mediated causes (acute disseminated encephalomyelitis (ADEM), autoimmune limbic encephalitis) that require urgent specific therapies. Furthermore, despite extensive investigations, the proportion of cases of unknown cause remains high. In-ICU care of patients with AE is a difficult task, given the diversity of etiologies and clinical presentations. Furthermore, additional studies such as magnetic resonance imaging (MRI) can be challenging to obtain in this population. Finally, there are no specific recommendations on the management and prognostic assessment of patients admitted to the ICU with AE. Present available data on the prognosis of patients with AE include both adult and pediatric cases, and focuses only on AE with identified causes. Prognosis of encephalitis in adult patients requiring ICU admission has been previously described only in retrospective single centre cohorts. To date, no prospective multicenter study on AE has been conducted in the specific population of adult critically ill patients. Furthermore, data on the diagnostic and prognostic contributions of magnetic resonance imaging (MRI) and electroencephalography studies in these patients are lacking The development of guidelines for standardized care in critically ill AE patients is needed, and will include management of early life support, prompt and exhaustive etiologic investigations, early administration of specific treatments and assessment of neurological prognosis. This study, which will focus on prognostic evaluation of severe AE in adults, appears crucial to support the development of such guidelines. Patients admitted to ICU for a suspicion of AE (acute encephalopathy and CSF pleocytosis \> 5 cells / microliter) will be eligible for inclusion. Patients admitted to ICU for a suspicion of AE (acute encephalopathy and CSF pleocytosis \> 5 cells / microliter) will be eligible for inclusion. Eligible patients will be included if they fulfil the IDSA 2013 diagnostic criteria for ""probable"" or ""confirmed"" encephalitis (see inclusion criteria). In patients without an obvious etiological diagnosis, an algorithm will be suggested to investigators to guide etiological investigations, according to the most recent recommendations (IDSA 2013). Aetiology of encephalitis will be described according to a priori-defined categories: 1) viral causes, 2) immune-mediated-causes, 3) bacterial or fungal meningitis with secondary encephalitic features, 4) undetermined causes. For each included patient, CSF and plasma samples will be stored at -80°C. A biobank will be created for subsequent analyses (etiological diagnosis, prognostic biomarkers). Outcomes will be assessed at 90 days and 365 days by contacting the patient or his relatives. The primary outcome is the score on the modified Rankin scale, which will be assessed 90 days after inclusion. Independent predictors of functional outcomes will be determined by multivariate logistic regression analysis.